OBJECTIVETo evaluate the clinical efficacy and safety of dexketoprofen trometamol in the treatment of patients with chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS).

METHODSA total of 115 patients with CP/CPPS were divided into a dexketoprofen trometamol group (n = 40), treated with dexketoprofen trometamol (25 mg, tid) and terazosin (2 mg, qn), an indometacin group (n = 40) given indometacin (25 mg, tid) and terazosin (2 mg, qn), and a terazosin group (n = 35) administered terazosin (2 mg, qn) only, all treated for 4 weeks. Scores on the NIH-chronic prostatitis symptom index (NIH-CPSI) were obtained before and after the treatment, and the efficacy and adverse events were observed and compared.

RESULTSThe NIH-CPSI scores were significantly improved after the treatment in all the three groups. The clinical efficacy was significantly better in the dexketoprofen trometamol and indometacin groups than in the terazosin group (P < 0.05), but with no significant difference between the former two (P > 0.05). The rates of adverse events were 10.00%, 18.57% and 27.50% in the dexketoprofen trometamol, terazosin and indometacin groups, significantly lower in the former two than in the latter one (P < 0.05).

CONCLUSIONThe combination of dexketoprofen trometamol with terazosin could effectively improve the clinical symptoms of CP/CPPS, better than terazosin in therapeutic efficacy and than indometacin in drug tolerance.

Adult ; Chronic Disease ; Humans ; Indomethacin ; administration & dosage ; therapeutic use ; Ketoprofen ; administration & dosage ; analogs & derivatives ; therapeutic use ; Male ; Pelvic Pain ; drug therapy ; Prazosin ; administration & dosage ; analogs & derivatives ; therapeutic use ; Prostatitis ; drug therapy ; Tromethamine ; administration & dosage ; analogs & derivatives ; therapeutic use

The goal of this study was to introduce a new method inducing an experimental brain injury model using ESWL(Extracorporeal Shock Wave Lithotripsy) and to evaluate findings of localized lesions on 1H MR imaging and the response of cerebral energy metabolism using a 31P MR spectroscope to the ESWL brain injury in cats. This study also examined effects of cerebral protective drugs. 1) There were no statistically significant changes in pH at all measurement points. 2) In the trauma group, initial decrease of PCr/Pi was seen at 30 to 60 minutes with return to control levels by 2 hours after injury(P < 0.05), followed by a second decline at 4 hours which lasted until 8 hours after injury. 3) Significant recovery in PCr/Pi(P < 0.05) was observed in both the THAM and dexamethasone treated groups at all measurement points and in the mannitol treated group only temporary recovery at 30 and 60 minutes (P < 0.05). 4) High intensity signals were seen on 1H MR imaging in traumatized animals. This study demonstrated the immediate and persistent recovery of cerebral energy metabolism using THAM or dexamethasone and an immediate but transient effect with mannitol in traumatized animals.
Adenosine Triphosphate/metabolism ; Animals ; Brain/*drug effects/metabolism ; Brain Injuries/etiology/metabolism/*prevention & control ; Cats ; Dexamethasone/*therapeutic use ; *Disease Models, Animal ; Energy Metabolism/*drug effects ; Hydrogen-Ion Concentration ; *Lithotripsy ; Magnetic Resonance Spectroscopy ; Phosphates/metabolism ; Phosphocreatine/metabolism ; Random Allocation ; Tromethamine/*therapeutic use